Search results
Results from the WOW.Com Content Network
Benzodiazepine withdrawal syndrome (BZD withdrawal) is the cluster of signs and symptoms that may emerge when a person who has been taking benzodiazepines as prescribed develops a physical dependence on them and then reduces the dose or stops taking them without a safe taper schedule.
Some of the symptoms that could possibly occur as a result of a withdrawal from benzodiazepines after long-term use include emotional clouding, [1] flu-like symptoms, [5] suicide, [11] nausea, headaches, dizziness, irritability, lethargy, sleep problems, memory impairment, personality changes, aggression, depression, social deterioration as ...
Withdrawal symptoms are the new symptoms that occur when the benzodiazepine is stopped. They are the main sign of physical dependence. [130] The most frequent symptoms of withdrawal from benzodiazepines are insomnia, gastric problems, tremors, agitation, fearfulness, and muscle spasms. [130]
Reducing the dose or discontinuing benzodiazepines may be indicated in such cases. Withdrawal symptoms can persist for quite some time after discontinuing benzodiazepines. Some common protracted withdrawal symptoms include anxiety, depression, insomnia, and physical symptoms such as gastrointestinal, neurologic, and musculoskeletal effects. The ...
According to Endo, Inc.’s recall, the Clonazepam being recalled is in cartons containing 60 tablets that are packed into 10 blister strips, containing six tablets each.
For withdrawal purposes, stabilisation with a long-acting agent such as diazepam is recommended before commencing withdrawal. Chlordiazepoxide (Librium), a long-acting benzodiazepine, is gaining attention as an alternative to diazepam in substance abusers dependent on benzodiazepines due to its decreased abuse potential. [ 16 ]
In addition to treating anxiety and seizures, clonazepam also has off-label uses for restless leg syndrome, acute mania, insomnia and the neurological condition tardive dyskinesia, which causes ...
In photos provided by Pennsylvania-based company it shows the potential mislabeling of a package of the Clonazepam tablets, USP 2 mg lot 550176501 with a carton description and NDC code of ...